A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas

Summary

This is a FIH, phase I/II, open label, multi-center study of DYP688 as a single agent. The purpose of this study is to characterize the safety, tolerability, and anti-tumor activity of DYP688 as a single agent in patients with metastatic uveal melanoma (MUM) and other melanomas harboring GNAQ/11 mutations.

Timeline

Start

2022-07-04

Primary completion

2027-10-01

Completion

2027-10-01

Publications

• Carlino MS, Kapiteijn E, Piperno-Neumann S, Sullivan RJ, Carvajal R, Dummer R, Gromke T, Hassel JC, Kee D, Ramelyte E, Shoushtari AN, Wei AZ, Enk A, Handel EE, Montazeri K, Ramon-Patino J, Richly H, Rodrigues M, Sandhu S, Smithy J, Speetjens FM, Milanez-Almeida P, Chaudhury A, Hoffmaster K, Ising M, Otero JA, RamKumar T, Reynolds A, Sharaby S, Werner L, Yerramilli-Rao P, Calvo E. An anti-PMEL antibody-drug conjugate with a Gq/11 inhibitor payload in GNAQ/GNA11-mutant melanomas: a phase 1 trial. Nat Med. 2026 Jul 13. doi: 10.1038/s41591-026-04518-z. Online ahead of print.

Drugs

Indications